Investment
Features
FeesSafety
Academy
More
Pluang+

KULR sells 333 Bitcoin to repay $20M Coinbase credit, retains strong Bitcoin holdings and debt-free status

Market News
31 Jul 2026
CrowdFundInsider
View Source
Bullish
pluang ai news

KULR Technology Group sold about 333 Bitcoin between July 9-23, 2026, at an average price of $64,538 each, generating roughly $21.5 million. The proceeds fully repaid the $20 million credit facility with Coinbase Credit, eliminating principal debt and freeing 565 Bitcoin previously pledged as collateral. This move reduces interest costs and liquidation risk while maintaining significant Bitcoin exposure and financial flexibility. KULR continues focusing on its core battery tech business and managing digital assets to support long-term shareholder value.

More News

Enbridge beats Q1 earnings and revenue estimates with $0.46 EPS and $29.32B revenue.

Enbridge beats Q1 earnings and revenue estimates with $0.46 EPS and $29.32B revenue.

Enbridge Inc. reported Q1 earnings per share of $0.46, surpassing analyst expectations of $0.43, despite a slight decline from $0.47 a year ago. The company posted a significant revenue beat, generating $29.32 billion compared to the expected $8.67 b...

Company Fundamentals
Bullish
1 hour ago
Global SaaS market to hit $600-650B by 2030 as AI and product-led growth reshape marketing.

Global SaaS market to hit $600-650B by 2030 as AI and product-led growth reshape marketing.

The global SaaS market, valued at $310-330 billion in 2025, is projected to nearly double to $600-650 billion by 2030, driven by cloud adoption, AI integration, and product-led growth strategies. SaaS companies are shifting marketing investments towa...

Market News
Bullish
1 hour ago
Exxon Mobil Q2 profit doubles despite EPS miss, boosted by higher oil prices and refining margins

Exxon Mobil Q2 profit doubles despite EPS miss, boosted by higher oil prices and refining margins

Exxon Mobil reported a strong Q2 2026 with profits surging to $14.5 billion, more than double the previous year, driven by higher oil prices and improved refining margins amid geopolitical tensions. However, adjusted earnings per share came in at $3....

Company Fundamentals
Neutral
2 hours ago
AbbVie beats Q2 2026 earnings and revenue estimates, raises full-year EPS forecast.

AbbVie beats Q2 2026 earnings and revenue estimates, raises full-year EPS forecast.

AbbVie reported adjusted diluted EPS of $3.65 for Q2 2026, surpassing analyst expectations of $3.60, and achieved revenues of $16.99 billion, exceeding forecasts of $16.78 billion. Strong growth in its Immunology and Neuroscience segments drove this ...

Company Fundamentals
Bullish
3 hours ago
Novo Nordisk's ZEUS trial shows no cardiovascular event reduction with ziltivekimab in high-risk patients.

Novo Nordisk's ZEUS trial shows no cardiovascular event reduction with ziltivekimab in high-risk patients.

Novo Nordisk announced that its ZEUS phase 3 trial testing ziltivekimab, an IL-6 pathway inhibitor, in over 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation did not reduce major adverse cardiovascul...

Company Fundamentals
Bearish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App